Main menu button

News

Carlsquare weekly market letter: Are we back to 1929 or 2008?
22 Mar 2023
Carlsquare weekly market letter: Are we back to 1929 or 2008?
Equity Research
Initiation of coverage, Biosergen: Make antifungals great again
20 Mar 2023
Initiation of coverage, Biosergen: Make antifungals great again
Equity Research Biosergen
Initiation of coverage Future Gaming: Reversed acquisition boosts Future Gaming
20 Mar 2023
Initiation of coverage Future Gaming: Reversed acquisition boosts Future Gaming
Equity Research Future Gaming
Carlsquare weekly market letter: Tech rebounds as Fed trembles
15 Mar 2023
Carlsquare weekly market letter: Tech rebounds as Fed trembles
Equity Research
Research Update Kancera, Q4 2022: Start of cancer trial expected shortly
15 Mar 2023
Research Update Kancera, Q4 2022: Start of cancer trial expected shortly
Equity Research Kancera
Research Update InCoax, Q4 2022: Positive follow-up orders from US operator
13 Mar 2023
Research Update InCoax, Q4 2022: Positive follow-up orders from US operator
Equity Research InCoax
First Impression InCoax, Q4 2022: Better than expected revenues, but low gross margin
10 Mar 2023
First Impression InCoax, Q4 2022: Better than expected revenues, but low gross margin
Equity Research InCoax
Carlsquare successfully advised VitaMoment on the majority investment by ARCUS Capital
09 Mar 2023
Carlsquare successfully advised VitaMoment on the majority investment by ARCUS Capital
Corporate Finance
Carlsquare weekly market letter: Big Evening Star in S&P 500
08 Mar 2023
Carlsquare weekly market letter: Big Evening Star in S&P 500
Equity Research
Research update Zinzino, Q4 2022: Profit growth in the cards for 2023
06 Mar 2023
Research update Zinzino, Q4 2022: Profit growth in the cards for 2023
Equity Research Zinzino
Research update Risk Intelligence, Q4 2022: Large global customers can give a boost
06 Mar 2023
Research update Risk Intelligence, Q4 2022: Large global customers can give a boost
Equity Research Risk Intelligence
Carlsquare successfully advised the shareholders of TorAlarm on the sale of a majority stake to BILD, a subsidiary of Axel Springer
02 Mar 2023
Carlsquare successfully advised the shareholders of TorAlarm on the sale of a majority stake to BILD, a subsidiary of Axel Springer
Corporate Finance
Carlsquare successfully advised Telio, a portfolio company of Charterhouse Capital Partners, on its acquisition of Gerdes Communications
01 Mar 2023
Carlsquare successfully advised Telio, a portfolio company of Charterhouse Capital Partners, on its acquisition of Gerdes Communications
Corporate Finance
Carlsquare weekly market letter: Can Junk lead the way?
01 Mar 2023
Carlsquare weekly market letter: Can Junk lead the way?
Equity Research
Carlsquare advised the shareholder of Arbeitsschutz-Express on the sale to Bunzl
28 Feb 2023
Carlsquare advised the shareholder of Arbeitsschutz-Express on the sale to Bunzl
Corporate Finance
Research update ALM Equity: Write-downs in associates affect results
28 Feb 2023
Research update ALM Equity: Write-downs in associates affect results
Equity Research ALM Equity
First impressions Zinzino, Q4 2022: Again, profitability above our expectations
28 Feb 2023
First impressions Zinzino, Q4 2022: Again, profitability above our expectations
Equity Research Zinzino
Carlsquare successfully advised Steuerbot, a subsidiary of Haufe Group, on its acquisition by Taxfix
27 Feb 2023
Carlsquare successfully advised Steuerbot, a subsidiary of Haufe Group, on its acquisition by Taxfix
Corporate Finance
Research Update SBB i Norden Q4 2022: Better earnings outweigh lower NAV
24 Feb 2023
Research Update SBB i Norden Q4 2022: Better earnings outweigh lower NAV
Equity Research SBB i Norden
First Impression SBB i Norden, Q4 2022: Better earnings capacity than expected
23 Feb 2023
First Impression SBB i Norden, Q4 2022: Better earnings capacity than expected
Equity Research SBB i Norden